

IX BIOPHARMA LTD.
(Company Registration Number 200405621W)
(Incorporated in the Republic of Singapore)

**PROPOSED PLACEMENT TO RAISE GROSS PROCEEDS OF NO LESS THAN S\$5,000,000
– COMPLETION OF PROPOSED PLACEMENT**

The Board of Directors of iX Biopharma Ltd. (the “**Company**”) (the “**Board**”) refers to its announcements dated 28 October 2025 and 30 October 2025 in relation to the Proposed Placement (collectively, the “**Announcements**”).

Unless otherwise defined, all capitalised terms used herein shall have the same meaning as ascribed to them in the Announcements.

Further to the Announcements, the Board is pleased to announce that the Proposed Placement was completed on 31 October 2025, pursuant to which 67,000,000 New Shares were allotted and issued by the Company on the terms and subject to the conditions as set out in the Placement Agreement. Following the completion of the Proposed Placement, the total number of issued Shares of the Company has increased from 888,843,413 Shares to 955,843,413 Shares. The New Shares rank pari passu with the existing Shares of the Company.

The New Shares are expected to be listed and quoted on Catalist on or around 5 November 2025 and trading of the New Shares will commence with effect from 9.00 a.m. on the same date.

By Order of the Board
IX BIOPHARMA LTD.

Eddy Lee Yip Hang
Chairman & CEO

31 October 2025

*This announcement has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “**Sponsor**”).*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone: (65) 6590 6881.